Table 1 Correlation of Fascin expression and clinicopathological features in TNBC.
From: Fascin enhances the vulnerability of breast cancer to erastin-induced ferroptosis
 | N = 76 | Fascin negative (N = 11) | Fascin positive (N = 65) | p value |
---|---|---|---|---|
Age (years, means ± SD) |  | 61.0 ± 7.20 | 50.8 ± 9.44 | 0.001 |
Menses status | Â | Â | Â | 0.008 |
Premenopausal | 35 (46.1%) | 1 (9.1%) | 34 (52.3%) | Â |
Postmenopausal | 41 (53.9%) | 10 (90.9%) | 31 (47.7%) | Â |
Tumour size | Â | Â | Â | 1 |
≤2 cm | 32 (42.1%) | 5 (45.5%) | 27 (41.5%) |  |
>2 cm | 44 (57.9%) | 6 (54.5%) | 38 (58.5%) |  |
N status | Â | Â | Â | 0.782 |
N0 | 42 (55.3%) | 7 (63.6%) | 35 (53.8%) | Â |
N+ | 34 (44.7%) | 4 (36.4%) | 30 (46.2%) | Â |
Ki67 | Â | Â | Â | 0.011 |
≤30 | 16 (21.1%) | 6 (54.5%) | 10 (15.4%) |  |
>30 | 60 (78.9%) | 5 (45.5%) | 55 (84.6%) | Â |
Surgery | Â | Â | Â | 0.338 |
Lumpectomy | 27 (35.5%) | 2 (18.2%) | 25 (38.5%) | Â |
Mastectomy | 49 (64.5%) | 9 (81.8%) | 40 (61.5%) | Â |
Radiotherapy | Â | Â | Â | 1 |
No | 33 (43.4%) | 5 (45.5%) | 28 (43.1%) | Â |
Yes | 43 (56.6%) | 6 (54.6%) | 37 (56.9%) | Â |
Chemotherapy | Â | Â | Â | 0.583 |
No | 7 (9.2%) | 2 (18.2%) | 5 (7.7%) | Â |
Yes | 69 (90.8%) | 9 (81.8%) | 60 (92.3%) | Â |
Recurrence | Â | Â | Â | 0.472 |
Yes | 4 (5.3%) | 1 (9.1%) | 3 (4.6%) | Â |
NO | 72 (94.7%) | 10 (90.9%) | 62 (95.4%) | Â |
Vital status | Â | Â | Â | 0.472 |
Dead | 4 (5.3%) | 1 (9.1%) | 3 (4.6%) | Â |
Alive | 72 (94.7%) | 10 (90.9%) | 62 (95.4%) | Â |